/
Cardiovascular
Cardiomyopathy
51
Pipeline Programs↗
137
Active Trials↗
30
Companies Involved↗
Cardiomyopathy is a moderately active landscape with 51 programs across 30 companies. The most active players are Alnylam Pharmaceuticals, Applied Therapeutics, Inc., Intellia Therapeutics. 15 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical24
Phase 14
Phase 28
Phase 315
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
39 of 42 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 96% of 51 pipeline programs.
Analysis
Trial Status
313
clinical trials
Completed108 · 35%
Recruiting81 · 26%
Unknown status32 · 10%
Active, not recruiting28 · 9%
Not yet recruiting24 · 8%
Terminated24 · 8%
Other16 · 5%
Clinical Trials
Trial Activity
313 trials
HCMR Re-Imaging Study
Recruiting·—·N/A·NCT07054073·314 enrolled
Page 1 of 21
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)